These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 12870431)

  • 1. siRNA-mediated antitumorigenesis for drug target validation and therapeutics.
    Lu PY; Xie FY; Woodle MC
    Curr Opin Mol Ther; 2003 Jun; 5(3):225-34. PubMed ID: 12870431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention in a mouse model of cervical cancer.
    Jonson AL; Rogers LM; Ramakrishnan S; Downs LS
    Gynecol Oncol; 2008 Nov; 111(2):356-64. PubMed ID: 18755502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short interfering RNA (siRNA): tool or therapeutic?
    Cejka D; Losert D; Wacheck V
    Clin Sci (Lond); 2006 Jan; 110(1):47-58. PubMed ID: 16336204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the development of siRNA-based therapeutics for cancer.
    Shen Y
    IDrugs; 2008 Aug; 11(8):572-8. PubMed ID: 18683092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potential of RNA interference against cancer.
    Takeshita F; Ochiya T
    Cancer Sci; 2006 Aug; 97(8):689-96. PubMed ID: 16863503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged gene silencing in hepatoma cells and primary hepatocytes after small interfering RNA delivery with biodegradable poly(beta-amino esters).
    Vandenbroucke RE; De Geest BG; Bonné S; Vinken M; Van Haecke T; Heimberg H; Wagner E; Rogiers V; De Smedt SC; Demeester J; Sanders NN
    J Gene Med; 2008 Jul; 10(7):783-94. PubMed ID: 18470950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. siRNA-mediated type 1 insulin-like growth factor receptor silencing induces chemosensitization of a human liver cancer cell line with mutant P53.
    Niu J; Xu Z; Li XN; Han Z
    Cell Biol Int; 2007 Feb; 31(2):156-64. PubMed ID: 17097318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy.
    Santel A; Aleku M; Keil O; Endruschat J; Esche V; Durieux B; Löffler K; Fechtner M; Röhl T; Fisch G; Dames S; Arnold W; Giese K; Klippel A; Kaufmann J
    Gene Ther; 2006 Sep; 13(18):1360-70. PubMed ID: 16625242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA.
    Spagnou S; Miller AD; Keller M
    Biochemistry; 2004 Oct; 43(42):13348-56. PubMed ID: 15491141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral delivery of siRNA and antisense oligonucleotides.
    Akhtar S
    J Drug Target; 2009 Aug; 17(7):491-5. PubMed ID: 19530907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LNA-antisense rivals siRNA for gene silencing.
    Jepsen JS; Wengel J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):188-94. PubMed ID: 15603252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA.
    Mahato RI; Cheng K; Guntaka RV
    Expert Opin Drug Deliv; 2005 Jan; 2(1):3-28. PubMed ID: 16296732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system.
    Pirollo KF; Rait A; Zhou Q; Hwang SH; Dagata JA; Zon G; Hogrefe RI; Palchik G; Chang EH
    Cancer Res; 2007 Apr; 67(7):2938-43. PubMed ID: 17409398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo.
    Griesenbach U; Kitson C; Escudero Garcia S; Farley R; Singh C; Somerton L; Painter H; Smith RL; Gill DR; Hyde SC; Chow YH; Hu J; Gray M; Edbrooke M; Ogilvie V; MacGregor G; Scheule RK; Cheng SH; Caplen NJ; Alton EW
    Respir Res; 2006 Feb; 7(1):26. PubMed ID: 16480492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. siRNA-based approaches in cancer therapy.
    Devi GR
    Cancer Gene Ther; 2006 Sep; 13(9):819-29. PubMed ID: 16424918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery.
    Golzio M; Mazzolini L; Ledoux A; Paganin A; Izard M; Hellaudais L; Bieth A; Pillaire MJ; Cazaux C; Hoffmann JS; Couderc B; Teissié J
    Gene Ther; 2007 May; 14(9):752-9. PubMed ID: 17344906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted delivery of small interfering RNA: approaching effective cancer therapies.
    Pirollo KF; Chang EH
    Cancer Res; 2008 Mar; 68(5):1247-50. PubMed ID: 18316585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNAi: a novel antisense technology and its therapeutic potential.
    Dallas A; Vlassov AV
    Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A
    Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis.
    Edovitsky E; Elkin M; Zcharia E; Peretz T; Vlodavsky I
    J Natl Cancer Inst; 2004 Aug; 96(16):1219-30. PubMed ID: 15316057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.